Editas Medicine Announces Results of 2026 Annual Meeting of Stockholders

Editas Medicine, Inc. held its 2026 Annual Meeting of Stockholders on June 17, 2026, where several key corporate matters were decided. Stockholders elected Bernadette Connaughton and Elliott Levy, M.D., as Class I directors to serve until the 2029 annual meeting. Additionally, the company's stockholders approved, on a non-binding advisory basis, the compensation paid to its named executive officers. Finally, the selection of PricewaterhouseCoopers LLP as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2026, was ratified. The filing details the specific vote counts for each proposal, including votes for, against, withheld, abstentions, and broker non-votes. No significant changes to clinical programs or financial guidance were disclosed in this filing.